APA

Liu F., Jiang C. C., Yan X. G., Tseng H., Wang C. Y., Zhang Y. Y., Yari H., La T., Farrelly M., Guo S. T., Thorne R. F., Jin L., Wang Q. & Zhang X. D. (2017). BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma. : Oncotarget.

Chicago

Liu Fen, Jiang Chen Chen, Yan Xu Guang, Tseng Hsin-Yi, Wang Chun Yan, Zhang Yuan Yuan, Yari Hamed, La Ting, Farrelly Margaret, Guo Su Tang, Thorne Rick F, Jin Lei, Wang Qi and Zhang Xu Dong. 2017. BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma. : Oncotarget.

Harvard

Liu F., Jiang C. C., Yan X. G., Tseng H., Wang C. Y., Zhang Y. Y., Yari H., La T., Farrelly M., Guo S. T., Thorne R. F., Jin L., Wang Q. and Zhang X. D. (2017). BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma. : Oncotarget.

MLA

Liu Fen, Jiang Chen Chen, Yan Xu Guang, Tseng Hsin-Yi, Wang Chun Yan, Zhang Yuan Yuan, Yari Hamed, La Ting, Farrelly Margaret, Guo Su Tang, Thorne Rick F, Jin Lei, Wang Qi and Zhang Xu Dong. BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma. : Oncotarget. 2017.